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Background: To determine the prevalence of patient-reported joint pain among patients with human
immunodeficiency virus (HIV)/chronic hepatitis C virus (HCV) coinfection, chronic HCV monoinfection, and HIV
monoinfection followed in hepatology and infectious disease outpatient practices.
Methods: Standardized interviews were performed among 79 HIV/HCV-coinfected, 93 HCV-monoinfected, and
30 HIV-monoinfected patients in a cross-sectional study within hepatology and infectious disease clinics at three
centers. The Multi-Dimensional Health Assessment Questionnaire was used to ascertain joint pain and associated
symptoms. Information on potential risk factors for joint pain was obtained during the interview and by chart
review. Logistic regression was used to determine adjusted odds ratios (aORs) with 95% confidence intervals
(CIs) of joint pain associated with risk factors of interest among chronic HCV-infected and HIV-infected patients.
Results: Joint pain was more commonly reported in HCV-monoinfected than HIV/HCV-coinfected (71% versus 56%;
p = 0.038) and HIV-monoinfected (71% versus 50%; p = 0.035) patients. A previous diagnosis of arthritis and current smoking
were risk factors for joint pain among HCV-infected patients (arthritis: aOR, 4.25; 95% CI, 1.84-9.81; smoking: aOR, 5.02; 95% CI,
2.15-11.74) and HIV-infected (arthritis: aOR, 5.36; 95% CI, 2.01-14.25; smoking: aOR, 6.07; 95% CI, 2.30-16.00) patients.
Conclusion: Patient-reported joint pain was prevalent among all three groups, but more common among chronic
HCV-monoinfected than either HIV/HCV-coinfected or HIV-monoinfected patients. A prior diagnosis of arthritis and
current smoking were risk factors for patient-reported joint pain among both HCV-infected and HIV-infected patients.
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Hepatitis C virus (HCV) infection is the most common
blood-borne infection in the United States and is a leading
cause of advanced liver disease. Over 4 million people in
the U.S. and more than 170 million people worldwide have
been infected with HCV infection [1,2]. Many extrahepatic* Correspondence: Alexis.ogdie@uphs.upenn.edu
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unless otherwise stated.manifestations have been associated with chronic HCV in-
fection, including dermatologic, neurologic, renal, and
rheumatic disorders [3-10]. While chronic HCV-induced
inflammation is generally thought to be a key contributor
to these manifestations, the mechanisms by which they
occur remain unclear [11].
Rheumatologists are frequently faced with managing
chronic HCV-infected patients with joint pain. However,
few published studies have evaluated: 1) the prevalence
of patient-reported joint pain among patients with
chronic HCV in the U.S., 2) how joint symptoms among
patients with chronic HCV affect quality of life andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HCV and human immunodeficiency virus (HIV) affects
the prevalence of patient-reported joint pain. HIV infection
has also been associated with rheumatic conditions, includ-
ing reactive arthritis, psoriatic arthritis, and arthralgias and
myalgias without identifiable inflammatory disease [12].
While HIV coinfection accelerates chronic HCV-related
liver fibrosis progression to cirrhosis and hepatic decom-
pensation, [13-15] the role of HIV/HCV coinfection on the
development of joint pain remains unknown.
The primary objective of this study was to determine
the prevalence of patient-reported joint pain (arthral-
gias) among patients with HIV/chronic HCV coinfection,
chronic HCV monoinfection, and HIV monoinfection
followed in hepatology and infectious disease clinics.
We hypothesized that there would be a higher preva-
lence of arthralgias in HIV/HCV-coinfected patients
compared to those who have chronic HCV or HIV
alone. Our second objective was to examine potential
risk factors for patient-reported joint pain among
chronic HCV-infected (i.e., HIV/HCV-coinfected and
HCV-monoinfected) and HIV-infected (i.e., HIV/HCV-
coinfected and HIV-monoinfected) patients.
Methods
Study design and setting
We performed a cross-sectional study among patients
with HIV/chronic HCV coinfection, chronic HCV
monoinfection, and HIV monoinfection. Consecutive
patients with chronic HCV and/or HIV infections were
recruited in hepatology and infectious disease clinics at
three tertiary care medical centers within Philadelphia
(Penn Presbyterian Medical Center [PPMC], Philadelphia
Veterans Affairs Medical Center [PVAMC], and the Hos-
pital of the University of Pennsylvania [HUP]). The
PPMC infectious disease outpatient practice specializes
in viral hepatitis care; hepatologists and infectious disease
physicians see patients concurrently in the HUP viral
hepatitis clinic; and the PVAMC outpatient infectious
disease and hepatology clinics are located within the
same practice space. Patients were enrolled between
November 2008 and March 2012.
Study patients
Participants were eligible for inclusion if they were between
18 and 80 years of age and had documentation of HIV
(HIV antibody- or RNA-positive) and/or chronic HCV
infection (HCV RNA-positive) in their medical record.
Exclusion criteria included the inability to either speak or
understand English or to provide informed consent.
Measurements
Participants were asked to complete an interviewer-
administered questionnaire that ascertained the presenceor absence of patient-reported joint pain over the one
week prior to the study visit, the duration of joint pain,
the joints affected, and previous diagnoses of joint disor-
ders or arthritis. Among patients reporting joint pain, an
interviewer administered the Multi-Dimensional Health
Assessment Questionnaire (MD-HAQ, version R780-
NP2) [16] given the highly varied reading skills and
medical literacy in the patient population surveyed. In-
terviews were standardized among the four question-
naire administrators (WGP, LM, SB, and AO). The MD-
HAQ includes a physical function score (range, 0 to 10),
emotional function score (0 to 9.9), a pain score (range,
0 to 10), global health assessment (range, 0 to 10),
fatigue scale (range, 0 to 10), ratings of painful joints,
responses to a review of systems, and basic demograph-
ics (e.g. age, sex, height, weight, education, employment
status and occupation). The MD-HAQ scores for phys-
ical function, pain, and global health status can be com-
bined into a composite index known as the Routine
Assessment of Patient Index Data (RAPID3; range, 0 to
30). In rheumatoid arthritis, a RAPID3 score of > 12 (on
a scale from 0–30) indicates high disease activity, a score
of 6.01-12 suggests moderate disease activity, a score of
3.01-6 suggests lower disease activity, and scores ≤ 3
indicate disease remission [17]. The MD-HAQ also in-
cludes three questions on “emotional function” (depres-
sion, anxiety, sleep disturbance), each ranging from 0 to
3.3 in 1.1 increments. These three scores were summed
to result in an “emotional function” score ranging from
0–9.9. The MD-HAQ includes a review of systems, in-
cluding symptoms such as dry mouth, dry eyes, numb-
ness and tingling in the extremities, myalgias, and
morning stiffness (a total of 60 symptoms are included
in the review of systems) and a visual analog scale for
fatigue. The MD-HAQ and RAPID3 have been validated
in patients with rheumatoid arthritis and have previously
been used in rheumatologic epidemiological studies
[18-20]. Additionally, the MDHAQ has been used in
clinical practice to evaluate many different diseases, in-
cluding osteoarthritis and fibromyalgia [21,22].
Medical records were also reviewed to abstract age at
study visit, sex, race, height and body weight, analgesic
medication use (e.g., use of narcotic analgesics, non-
steroidal anti-inflammatory drugs, acetaminophen, or
gabapentin), medical comorbidities (i.e., diabetes melli-
tus, hypertension, congestive heart failure, coronary
artery disease, hyperlipidemia, obstructive sleep apnea,
chronic kidney disease, psoriasis, inflammatory bowel
disease, lymphoma, thyroid disease, history of arthritis,
anxiety disorder, depression), HIV-related data (CD4 cell
count, HIV RNA level, use of antiretroviral therapy),
HCV-related data (HCV genotype, HCV RNA level,
current or prior interferon-based HCV therapy; hepatic
decompensation diagnoses [ascites, spontaneous bacterial
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cephalopathy]; hepatocellular carcinoma), relevant social
history (history of smoking, alcohol use, intravenous drug
use, homelessness, incarceration, blood transfusion), and
most recently recorded laboratory results of total bilirubin,
asparate aminotransferase (AST), alanine aminotransferase
(ALT), albumin, international normalized ratio (INR), white
blood cell count, hemoglobin, and platelet count.
Data analysis
The prevalence of joint pain was determined and
expressed as a point estimate (percent) and 95% confi-
dence interval (CI) within each group. Descriptive statis-
tics were used to compare characteristics between groups
(HIV/HCV-coinfected, HCV-monoinfected, and HIV-
monoinfected). Differences between groups were deter-
mined using Chi-square or Fisher’s exact tests, when
appropriate, for categorical data, and Wilcoxon rank-
sum tests for continuous data. Logistic regression was
used to determine adjusted odds ratios (aORs) with 95%
CIs of joint pain associated with risk factors of interest
among chronic HCV-infected (i.e., HIV/HCV-coin-
fected and HCV-monoinfected) and HIV-infected (i.e.,
HIV/HCV-coinfected and HIV-monoinfected) patients.
Variables evaluated as risk factors for joint pain in-
cluded age, sex, race, history of arthritis, history of
anxiety disorder or depression, obesity (body mass
index [BMI] > 30 kg/m2), AST, ALT, current HCV
therapy, use of analgesic medications, HCV genotype
(in chronic HCV-infected patients only), and CD4 cell
count (in HIV-infected patients only). Since HCV treat-
ment has been associated with arthralgias, we per-
formed a sensitivity analysis in which we excluded
patients currently utilizing this therapy and repeated
the analyses above.
Ethical approval
This study was approved by the Institutional Review
Boards of the University of Pennsylvania and PVAMC.
Written informed consent was obtained from all patients
participating in the study.
Results
A total of 202 participants were enrolled (79 HIV/HCV-
coinfected; 93 HCV-monoinfected; 30 HIV-monoinfected).
The characteristics of each group are presented in Table 1.
Among the three groups, age and sex distributions were
similar. Over half of participants were black (African-
American or Caribbean-American decent). HCV geno-
type 1 was the most common genotype among chronic
HCV patients. Median HCV RNA levels were higher in
coinfected than HCV-monoinfected patients. Few chronic
HCV-infected patients were currently receiving HCV
therapy but approximately half previously received HCVtreatment. Three patients reported a prior diagnosis of
rheumatoid arthritis (2 with HCV monoinfection, 1 with
HCV/HIV coinfection), one with systemic lupus erythe-
matosus (HCV-monoinfected), one with ankylosing spon-
dylitis (HIV-monoinfected), and one with inflammatory
arthritis not otherwise specified (HCV-monoinfected). Use
of analgesic medications was similar among the groups.
The mean BMI was significantly lower in coinfected and
HIV-monoinfected patients. Liver aminotransferase levels
were higher and platelet counts were lower in coinfected
and HCV-monoinfected patients. Other laboratory values
did not significantly differ between the groups (Additional
file 1: Table S1).
Over half of the patients reporting joint pain also self-
reported depression and anxiety on the MD-HAQ. De-
pression was reported by 50% of HCV-monoinfected,
80% of HIV-monoinfected, and 64% HIV/HCV-coin-
fected patients. Similarly, anxiety was reported by 51% of
HCV-monoinfected, 67% of HIV-monoinfected, and 77%
of coinfected patients.
Joint pain was more commonly reported among HCV-
monoinfected than coinfected (71% versus 56%; p =
0.038) or HIV-monoinfected patients (71% versus 50%;
p = 0.035). After adjustment for age and sex, HCV-
monoinfected patients were 1.9-fold more likely to re-
port joint pain compared to coinfected patients (aOR,
1.94; 95% CI, 1.02-3.67) and 2.4-fold more likely to re-
port arthralgias compared to HIV-monoinfected patients
(aOR, 2.43; 95% CI, 1.03-5.72). No differences in the
prevalence of joint pain were observed between coin-
fected and HIV-monoinfected patients (56% versus 50%;
p = 0.59). HIV/HCV coinfection remained unassociated
with arthralgias compared to HIV monoinfection after
adjustment for age and sex (aOR, 1.25; 95% CI, 0.54-
2.92). A sensitivity analysis excluding chronic HCV-
infected patients currently on HCV therapy (n = 22) re-
vealed similar proportions of chronic HCV-infected per-
sons reporting joint pain (data not shown).
Among all three groups, fingers, knees, and back were
the most frequently cited areas of joint pain (Figure 1).
The distribution of painful joints was similar among the
groups, although HCV-monoinfected patients more
commonly reported finger pain compared to coinfected
(41% versus 27%; p = 0.035) and HIV-monoinfected (41%
versus 23%; p = 0.067) patients.
MD-HAQ results among participants reporting joint
pain are reported in Table 2. The mean (SD) MD-HAQ
among participants reporting joint pain was 6.0 (2.77),
and the mean (SD) RAPID3 was 12.9 (5.46). The RAPID3
components did not significantly differ by HIV/HCV sta-
tus. The mean (SD) duration of morning stiffness among
participants reporting joint pain was 57.3 (158.1) minutes.
Symptoms of dry mouth, ascertained by the MD-HAQ,
were less commonly reported among HIV-monoinfected
Table 1 Baseline characteristics of human immunodeficiency virus (HIV)/chronic hepatitis C virus (HCV)-coinfected,
chronic HCV-monoinfected, and HIV-monoinfected participants
HCV/HIV- HCV- HIV- P-value*
Coinfected Monoinfected Monoinfected HCV/HIV HCV/HI
N = 79 N = 93 N = 30 vs HCV V vs HIV
Site (n, %) <0.001 <0.001
HUP 2 (3%) 35 (38%) 0 (0%)
PPMC 35 (44%) 20 (22%) 1 (3%)
PVAMC 42 (53%) 38 (41%) 29 (97%)
Age (Median, IQR) 55 (43–64) 57.5 (53.5-61) 54 (51–60) 0.04† NS†
Sex (n, %) NS NS
Male 68 (86%) 77 (83%) 28 (93%)
Female 11 (14%) 16 (17%) 2 (7%)
Race (n, %) 0.001 NS
Caucasian 9 (11%) 35 (38%) 5 (17%)
Black 64 (81%) 50 (54%) 24 (80%)
Hispanic 4 (5%) 3 (3%) 0 (0%)
Other 2 (3%) 2 (2%) 1 (3%)
BMI (kg/m2) 25.0 29.2 27.2 <0.001† 0.05†
Median (IQR) (22.5-29.0) (25.5-33.2) (25.0-33.2)
Current smoker (n, %) 29 (37%) 37 (40%) 9 (30%) NS NS
HCV Treatment (n, %) 0.01 N/A
Current 4 (5%) 17 (18%) 0 (0%)
Past 22 (28%) 31 (33%) 0 (0%)
Never 53 (67%) 45 (48%) 30 (100%)
HCV Genotype (n, %) NS N/A
1 (A or B) 70 (89%) 60 (65%) 0 (0%)
2 1 (1%) 5 (5%) 0 (0%)
3 1 (1%) 4 (4%) 0 (0%)
HCV RNA (IU/mL) 1.37 0.62 N/A 0.02† N/A
Median in million (IQR) (0.44-4.63) (0.03-2.70)
CD4 count (cells/mm3) 474 N/A 480 N/A NS†
Median (IQR) (358–666) (295–673)
Antiretroviral 67 (85%) 0 (%) 26 (87%) N/A NS
therapy (n, %)
Previous arthritis diagnosis‡ (n, %) 37 (40%) 28 (35%) 8 (27%) NS NS
Analgesic medication use (n, %) NS NS
Any 41 (52%) 49 (53%) 20 (67%)
Opiate 15 (19%) 15 (16%) 4 (13%)
Gabapentin 17 (22%) 11 (12%) 8 (27%)
NSAIDs 21 (27%) 23 (25%) 10 (33%)
Tylenol 10 (13%) 18 (19%) 9 (30%)
Abbreviations: HUP = Hospital of University of Pennsylvania, PPMC = Penn Presbyterian Medical Center, PVAMC = Philadelphia Veterans Affairs Medical Center,
BMI = body mass index, NS = Not significant (p > 0.05), N/A = Not Applicable.
‡Previous arthritis diagnosis included rheumatoid arthritis (N = 4), osteoarthritis (N = 46), ankylosing spondylitis (N = 1), systemic lupus erythematosus (N = 1), and
patient reported “arthritis” but unknown type (N = 22). One patient carried more than one diagnosis.
†Wilcoxan-rank sum test, remainder of the p-values were calculated using the chi2 test.
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Figure 1 Sites of joint pain, by human immunodeficiency virus (HIV)
and chronic hepatitis C virus (HCV) Status (%).The distribution of
painful joints was similar among the groups, although HCV-
monoinfected patients more commonly reported finger pain
compared to coinfected (41% versus 27%; p = 0.035) and HIV-
monoinfected (41% versus 23%; p = 0.067) patients. The p-values for
the remainder of the comparisons were >0.05.
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monoinfected (20% versus 48%; p = 0.04) patients. Coin-
fected participants were more likely to report myalgias
than HCV-monoinfected (43% versus 27%; p = 0.06) or
HIV-monoinfected (43% versus 7%; p = 0.01) persons.
Additionally, patients with HIV/HCV coinfection were
more likely to report numbness or tingling of the extrem-
ities compared to patients with HCV monoinfection (41%
versus 27%; p = 0.14) or HIV monoinfection (41% versus
7%; p = 0.01).
A previous diagnosis of arthritis (aOR, 4.25; 95% CI,
1.84-9.81) and current smoking (aOR, 5.02; 95% CI,
2.15-11.74) were risk factors for self-reported joint pain
among chronic HCV-infected patients (Table 3). These
associations remained when persons currently receiving
HCV therapy were excluded (data not shown). Among
HIV-infected patients, current smoking (aOR, 6.07; 95%
CI, 2.30-16.00) and a previous diagnosis of arthritis (aOR,
5.36; 95% CI, 2.01-14.25) were also associated with
arthralgias.Discussion
This cross-sectional study demonstrated that joint pain
was commonly reported and associated with diminished
functional status and emotional well-being among
patients with chronic HCV and/or HIV infection. The
prevalence of joint pain was significantly higher among
HCV-monoinfected than HIV/HCV-coinfected and HIV-
monoinfected patients. Over two-thirds of patients with
chronic HCV monoinfection reported joint pain, while
approximately half of coinfected and HIV-monoinfected
patients reported arthralgias.Our study extends results of prior cross-sectional ana-
lyses, which have reported that 67-81% of chronic
HCV-infected patients complain of musculoskeletal
pain [23,24]. Tsui et al. [25] found that HIV/HCV coin-
fection was more commonly associated with musculo-
skeletal pain compared to HIV-monoinfection (aOR,
1.45; 95% CI, 1.06-1.97), and adjusting for inflammatory
cytokine levels and depression did not change these
results. Consistent with our results, Cacoub et al. [26]
found that HIV/HCV-coinfected patients less commonly
had arthralgias compared with HCV-monoinfected pa-
tients (5% versus 29%). However, none of these studies
directly compared joint complaints among HIV/HCV-
coinfected, HCV-monoinfected, and HIV-monoinfected
patients, as was performed in this study.
The etiology of joint pain in chronic HCV infection
remains unclear. Immune activation, direct viral particle
deposition in the synovium, and the high prevalence of
concomitant mood disorders might be important con-
tributors to the arthralgias commonly reported by
chronic HCV-infected patients [10,27,28].
The differences in the prevalence of joint pain among
the three study groups raise important questions for
further study. Hypothesized explanations for these find-
ings include differences in unmeasured environmental
exposures among the groups or potentially a decrease in
local inflammation related to immune dysfunction in
HIV infection, resulting in a decreased effect of chronic
HCV in the HIV/HCV-coinfected patients [29,30] Add-
itionally, HIV-infected patients may be more tolerant of
joint discomfort due to higher priority placed on more
serious complications of their underlying disease. In
general, HCV-infected patients with joint pain had a
high prevalence of self-reported depression, anxiety,
and sleep disturbance. Depression and anxiety could
have contributed to a higher prevalence of joint pain re-
ported by this group since mood and joint pain are
strongly linked.
We found that current smoking was strongly associ-
ated with joint pain. Smoking has been associated with
musculoskeletal pain and the development of rheuma-
toid arthritis [31] In addition, smoking is associated
with worse disease activity in patients with rheumatoid
arthritis [32]. However, smoking and its link to joint
pain in patients with chronic HCV has not previously
been reported. Importantly, smoking is a modifiable risk
factor. Further research is needed to determine whether
joint pain in patients with chronic HCV improves with
smoking cessation.
7We found that nearly half of patients with chronic
HCV infection (both HCV-monoinfected and HIV/
HCV-coinfected) and joint pain self-reported 20 or
more symptoms which has previously been reported to
indicate a fibromyalgia diagnosis [33]. Fibromyalgia has
Table 2 Multidimensional Health Assessment Questionnaire results among participants reporting joint pain
HCV/HIV- HCV- HIV-
Coinfected Monoinfected Monoinfected
Physical Function Score (Mean(SD)) 2.4 (2.0) 2.6 (1.5) 3.3 (2.1)
Pain (Mean(SD)) 6.5 (2.7) 5.6 (2.7) 6.2 (3.2)
Patient Global (Mean(SD)) 3.9 (3.3) 4.4 (2.4) 4.9 (1.7)
RAPID3 (Mean(SD)) 12.8 (6.3) 12.6 (4.9) 14.3 (5.6)
Emotional Score*(Mean(SD)) 4.2 (2.7) 3.7 (2.4) 3.7 (2.3)
Total Symptoms (Mean(SD))** 18.6 (10.4) 17.6 (9.8) 14.2 (10.8)
Depression, n (%) 28 (64%) 33 (50%) 12 (80%)
Anxiety, n (%) 34 (77%) 34 (51%) 10 (67%)
Sleep Disturbance, n (%) 32 (73%) 41 (62%) 10 (67%)
Dry Eyes, n (%) 6 (14%) 19 (29%) 0 (0%)
Dry Mouth n (%) 20 (45%) 32 (48%) 3 (20%)
Numbness/tingling n (%) 18 (41%) 18 (27%) 1 (7%)
Myalgias, n (%) 19 (43%) 17 (26%) 1 (7%)
Morning Stiffness, n (%) 29 (66%) 44 (67%) 8 (53%)
Fatigue Scale (Mean(SD)) 4.53 (3.68) 4.73 (3.44) 3.97 (3.82)
≥20 Symptoms Reported 42 (45%) 43 (54%) 7 (23%)
Only patients reporting joint pain completed the MD-HAQ. *The MD-HAQ includes an emotional function assessment in which depression, anxiety and sleep
disturbance each ranked as none (0), mild (1.1), moderate (2.2) or severe (3.3). The total “emotional score” is the combined sum of these three components
(range 0–9.9).
**The MD-HAQ contains a 60-item review of systems (including depression, anxiety, sleep disturbance, dry eyes, dry mouth, numbness/tingling, myalgias, and
morning stiffness. There is additionally a visual analog scale for fatigue.
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chronic HCV although the reason for this association is
unclear [27,28].
Our study was limited by its cross-sectional design,
use of convenience sampling, our inability to perform
physical examinations and obtain imaging studies to
rule out osteoarthritis, and the relatively small sample.
In particular, there is the possibility that patients with
joint pain may have been more likely to complete the
survey. Additionally, we were unable to determine
the specific etiologies for the joint pain. While many
patients reported a diagnosis of arthritis, we did notTable 3 Factors associated with joint pain in chronic hepatitis
virus-infected participants
HCV
Univariable models (Unadjusted) Mult
OR (95% CI) OR (9
Co-infection 0.51 (0.27-0.97) 0.49
Age (cont) 1.01 (0.96-1.06)
Female Sex* 0.95 (0.41-2.23)
Current Smoker 3.50 (1.71-7.18) 5.02
Obesity (BMI > 30) 1.85 (0.90-3.79) 1.29
Previous Diagnosis of Arthritis† 4.47 (2.11-9.48) 4.25
*Males are the referent group. †Previous arthritis diagnosis included rheumatoid ar
(N = 1), osteoarthritis (N = 46), and patient reported “arthritis” but unknown type (Nconfirm these diagnoses on physical examination or
further testing. Furthermore, some patients were
prescribed analgesic medications, and these patients
might have less commonly self-reported joint pain.
Finally, our study evaluated patient-reported joint
complaints present within the one week prior to the
survey date. Thus, there may have been patients with
intermittent joint pain who were not identified in this
study. However, use of the one week time frame limits
the risk of recall bias and is the time period specified
on the MD-HAQ for assessment of disease activity in
rheumatoid arthritis.C virus-infected and human immunodeficiency
HIV
ivariable model Univariable models (Unadjusted) Final model




(2.15-11.74) 5.43 (2.18-13.52) 6.07 (2.30-16.00)
(0.57-2.92) 1.70 (0.68-4.29)
(1.84-9.81) 4,74 (1.90-11.81) 5.36 (2.01-14.25)
thritis (N = 4), ankylosing spondylitis (N = 1), systemic lupus erythematosus
= 22). Abbreviations: BMI = body mass index.
Ogdie et al. BMC Musculoskeletal Disorders  (2015) 16:93 Page 7 of 8Conclusions
Among patients with HIV and/or chronic HCV infec-
tions, joint pain was prevalent. HCV-monoinfected
patients more frequently reported arthralgias compared
to HIV/HCV-coinfected or HIV-monoinfected persons.
These results suggest that joint pain remains a major
health concern and a determinant of health-related qual-
ity of life among these patients. Providers should seek to
address modifiable risk factors for joint pain (e.g., smok-
ing cessation) in such persons. Future studies should
determine the etiologies and strategies for management
of joint pain, including fibromyalgia, in patients with
chronic HCV and HIV infection, as well as the mecha-
nisms for modulation of joint symptoms in HIV/HCV-
coinfected patients.
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